The treatment landscape for advanced urothelial carcinoma has drastically improved, yet global access to novel agents remains unequal. Thus, answering crucial clinical questions regarding platinum-backbone optimization, chemotherapy and treatment duration, and metastasis-directed therapies is essential to maximize outcomes with currently available, widespread standards of care.
- Jorge Esteban-Villarrubia
- Guillermo de Velasco